Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB)’s traded shares stood at 0.15 million during the last session, with the company’s beta value hitting -0.20. At the close of trading, the stock’s price was $1.17, to imply an increase of 8.27% or $0.09 in intraday trading. The CNTB share’s 52-week high remains $1.60, putting it -36.75% down since that peak but still an impressive 56.41% since price per share fell to its 52-week low of $0.51. The company has a valuation of $64.72M, with an average of 82920.0 shares in intraday trading volume over the past 10 days and average of 131.09K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Connect Biopharma Holdings Ltd ADR (CNTB), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give CNTB a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.22.
Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) trade information
After registering a 8.27% upside in the last session, Connect Biopharma Holdings Ltd ADR (CNTB) has traded red over the past five days. The 5-day price performance for the stock is 20.48%, and 44.18% over 30 days. With these gigs, the year-to-date price performance is -18.80%. Short interest in Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB) saw shorts transact 17062.0 shares and set a 0.21 days time to cover.
The extremes give us $1.5 and $1.5 for target low and target high price respectively. As such, CNTB has been trading -28.21% off suggested target high and -28.21% from its likely low.
Connect Biopharma Holdings Ltd ADR (CNTB) estimates and forecasts
The rating firms project that company’s revenue will shrink -100.00% compared to the previous financial year.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 7.78% for the past 5-year period. While 2025 is set for a -207.85% return in earnings, projections for the next 5 years are at -24.12% annually.
CNTB Dividends
Connect Biopharma Holdings Ltd ADR has its next earnings report out on 2023-Sep-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Connect Biopharma Holdings Ltd ADR (NASDAQ:CNTB)’s Major holders
Connect Biopharma Holdings Ltd ADR insiders hold 40.65% of total outstanding shares, with institutional holders owning 43.97% of the shares at 74.09% float percentage. In total, 43.97% institutions holds shares in the company, led by BML CAPITAL MANAGEMENT, LLC. As of 2024-06-30, the company held over 2.04 million shares (or 3.7053% of shares), all amounting to roughly $3.11 million.
The next major institution holding the largest number of shares is UBS OCONNOR LLC with 0.51 million shares, or about 0.9261% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $0.78 million.
Going by data provided on Apr 30, 2025, Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund holds roughly 23.32 shares. This is just over 0.04% of the total shares, with a market valuation of $27268.0
